ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.97
0.00%
US Tech 100
20,108.00
-0.09%
S&P 500
5,917.11
0.00%
US Dollar vs CAD
1.39647
-0.04%
Bitcoin
98,003.28
3.86%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Coherus BioSciences Inc (CHRS) Share Price

Coherus BioSciences Inc

Coherus BioSciences Inc (CHRS)

NASDAQ
1.10
0.28
(33.90%)
Closed November 20 3:00PM
Delayed by 15 minutes
0.9978
-0.1022
( -9.29% )
Pre Market: 5:55AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.9978
Bid
0.9855
Ask
1.01
Volume
45,018
0.00 Day's Range 0.00
0.6655 52 Week Range 3.70
Market Cap
114.96M
Previous Close
1.10
Open
-
Last Trade
100
@
0.9978
(formt)
Last Trade Time
05:55:30
Financial Volume
-
VWAP
-
Average Volume (3m)
2,678,346
Shares Outstanding
115,213,407
Dividend Yield
-
PE Ratio
-0.53
Earnings Per Share (EPS)
-2.06
Revenue
257.24M
Net Profit
-237.89M

About Coherus BioSciences Inc

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the... Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.coherus.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Coherus BioSciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CHRS. The last closing price for Coherus BioSciences was US$1.10. Over the last year, Coherus BioSciences shares have traded in a share price range of US$ 0.6655 to US$ 3.70.

Coherus BioSciences currently has 115,213,407 shares outstanding. The market capitalization of Coherus BioSciences is US$126.73 million. Coherus BioSciences has a price to earnings ratio (PE ratio) of -0.53.

Ask ADVFN Intelligence (AI)

Coherus BioSciences (CHRS) Options Flow Summary

CHRS Options Flow

Overall Flow

Bullish

Net Premium

414k

Calls / Puts

100.00%

Buys / Sells

800.00%

OTM / ITM

0.00%

Sweeps Ratio

9.09%

CHRS Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 06 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 06 2024
Edgar (US Regulatory)

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter – – UDENYCA labeling and packaging production resuming at third-party contract...

November 06 2024
GlobeNewswire Inc.

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter 2024 financial results will be released after...

October 30 2024
GlobeNewswire Inc.

Form 8-K - Current report

September 13 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

August 09 2024
Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans

August 08 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 08 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 08 2024
Edgar (US Regulatory)

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

– Net revenue of $65.0 million in Q2 2024 – – CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination with LOQTORZI – – Bryan McMichael...

August 08 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.184922.74572518140.81291.130.737986740.92711515CS
40.186322.95748613680.81151.130.665531708230.81593903CS
12-0.3822-27.69565217391.381.490.665526783460.9522121CS
26-1.0722-51.79710144932.072.170.665521445391.20911079CS
52-1.0622-51.56310679612.063.70.665531379182.04933222CS
156-17.6322-94.644122383318.63190.665522408914.29151663CS
260-18.2822-94.824688796719.2823.030.665517521117.35453074CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
US$ 1.98
(102.04%)
16.34M
AKTSAkoustis Technologies Inc
US$ 0.1321
(51.66%)
57.77M
PETWag Group Company
US$ 0.303
(44.22%)
18.31M
ESGROEnstar Group Ltd
US$ 28.00
(40.92%)
28
CCECCapital Clean Energy Carriers Corporation
US$ 24.99
(34.72%)
11
WSBFWaterstone Financial Inc
US$ 9.00
(-40.98%)
4
TRSTriMas Corporation
US$ 15.62
(-40.79%)
3
BCAXBicara Therapeutics Inc
US$ 11.00
(-40.15%)
212
PYXSPyxis Oncology Inc
US$ 2.43
(-36.39%)
209.56k
XNCRXencor Inc
US$ 15.11
(-36.30%)
2
AKTSAkoustis Technologies Inc
US$ 0.1321
(51.66%)
57.77M
PETWag Group Company
US$ 0.303
(44.22%)
18.31M
WORXSCWorx Corporation
US$ 1.98
(102.04%)
16.34M
XTKGX3 Holdings Company Ltd
US$ 0.0775
(-13.89%)
10.83M
CRKNCrown Electrokinetics Corporation
US$ 0.9853
(25.41%)
5.59M

CHRS Discussion

View Posts
The GidDy uP Kid The GidDy uP Kid 16 hours ago
Nice day todaY...
👍️0
The GidDy uP Kid The GidDy uP Kid 2 weeks ago
https://schrts.co/sMeAHIGh
👍️0
The GidDy uP Kid The GidDy uP Kid 2 weeks ago
 daily psar fliPPed to the Bullish Buy Side…
👍️0
The GidDy uP Kid The GidDy uP Kid 2 weeks ago
76 after hours… 
👍️0
The GidDy uP Kid The GidDy uP Kid 2 weeks ago
 aDDing… 
👍️0
The GidDy uP Kid The GidDy uP Kid 2 weeks ago
 back to greeN… 
👍️0
The GidDy uP Kid The GidDy uP Kid 2 weeks ago
Nice daily Bullish Engulfing candle… 
https://schrts.co/TkiuQvJe
👍️0
The GidDy uP Kid The GidDy uP Kid 3 weeks ago
inverted HammeR off the lower Keltner line, with the daily psar flip to the Bullish side quickly approaching; furthermore, pinching in here on the pincher 🤏 …  
https://schrts.co/IJcPqwzg
👍️0
The GidDy uP Kid The GidDy uP Kid 3 weeks ago
...
👍️0
boytroy88 boytroy88 1 month ago
It's even lower now. ☹️
👍️0
Monksdream Monksdream 2 months ago
CHRS new 52 week low
👍️0
Monksdream Monksdream 4 months ago
CHRS under $2
👍️0
Monksdream Monksdream 4 months ago
CHRS under $2
👍️0
glenn1919 glenn1919 4 months ago
CHRS...................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 7 months ago
CHRS under $3
👍️0
frans frans 9 months ago
short interest about 28.000.000 milj.up 7% today
👍️0
Mile High Marauder Mile High Marauder 9 months ago
Here is short interest link

https://www.nasdaq.com/market-activity/stocks/chrs/short-interest
👍️0
frans frans 9 months ago
you know how many shorts we have here to cover ????
my last buy was 2.08
👍️0
Mile High Marauder Mile High Marauder 9 months ago
I think selling these non core assets, with the probability of selling more has greatly diminished the need to raise money and has put some pressure on the shorts to cover some of this massive short. IMO
👍️ 1
frans frans 9 months ago
Coherus’ oncology assets include the UDENYCA® (pegfilgrastim-cbqv) franchise, with three FDA-approved presentations; LOQTORZI™ (toripalimab-tpzi), an FDA-approved, next-generation PD-1 inhibitor; and an immuno-oncology pipeline of next-generation tumor microenvironment oncology drug candidates.

Closing is anticipated in from jan 22
👍️0
Mile High Marauder Mile High Marauder 9 months ago
What fda news are u looking for?
👍️0
frans frans 9 months ago
up 14 % FDA news is coming
👍️0
frans frans 10 months ago
MM's we see an small cover now ? or company sell more ??,
👍️0
Mile High Marauder Mile High Marauder 10 months ago
27million share short. I wonder what the true valuation of the company is? I sure hope the shorts have to cover some day. I can’t say I’ve Seen a short this large on a listed stock. Implosion or explosion ,I guess only time will tell.
👍️0
moonurneighbor moonurneighbor 10 months ago
I think they are preparing for a sale
👍️0
Awl416 Awl416 10 months ago
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
👍️0
frans frans 10 months ago
up from here now for the 1e FDA news
👍️0
frans frans 10 months ago
company dump big big here
👍️0
frans frans 10 months ago
have we an new company dump now ???????
👍️0
frans frans 10 months ago
now up from here and wait on FDA news (should be good)
👍️0
glenn1919 glenn1919 11 months ago
CHRS...........................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
👍️0
tbonaces80 tbonaces80 11 months ago
Cup and handle formed
👍️0
tbonaces80 tbonaces80 11 months ago
We will test HOD. HH and HL’s
👍️0
Mile High Marauder Mile High Marauder 11 months ago
I find it hard to believe they’re going to dilute this company by 40% at this point Or at this price but you never know.
👍️0
Sierra20 Sierra20 11 months ago
Offering?
👍️0
eneels01 eneels01 11 months ago
Company needs to issue 40M shares at $2/sh. This would raise $80M, which would be enough to get through mid 2025…
👍️0
Mile High Marauder Mile High Marauder 12 months ago
21 million share short!! What is going on!
👍️0
Monksdream Monksdream 1 year ago
CHRS new 52 week low
👍️0
frans frans 1 year ago
about end dec.23 finish tests 400 peoples - FDA commercialization about june 24 if no problems
👍️0
eneels01 eneels01 1 year ago
Wow, instead of having a chance to go to $9, this stock has more of a chance to hit $1 by 2024. Oh well, I will just keep averaging down and sell when it eventually hits $5 again. Unfortunately that might not take place until 2025 or even 2026…
👍️0
frans frans 1 year ago
I selled and come back begin jan 24 after finish test 400 peoples about end dec. 23
👍️0
Mile High Marauder Mile High Marauder 1 year ago
Any idea who has this much stock to sell? I don’t see very many 5% holders.
👍️0
frans frans 1 year ago
what is going on here ??
👍️0
TimeFades TimeFades 1 year ago
Yup
👍️0
Monksdream Monksdream 1 year ago
For now
👍️0
TimeFades TimeFades 1 year ago
Looking strong
👍️0
Monksdream Monksdream 1 year ago
Few and far between in the biomed sector this year
👍️0
frans frans 1 year ago
slowly up from here
👍️0
Monksdream Monksdream 1 year ago
CHRS morning rally
👍️0
TimeFades TimeFades 1 year ago
Back in
👍️0

Your Recent History

NASDAQ
CHRS
Coherus BioSciences
DOWI
HKDOW
DJ Hong Kong
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved